1,969 Eli Lilly and Company $LLY Shares Acquired by Summit Global Investments

Posted by Brian Himes on Nov 2nd, 2026

Eli Lilly and Company logo Summit Global Investments raised its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 18.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,376 shares of the company’s stock after acquiring an additional 1,969 shares during the period. Eli Lilly and Company makes up approximately 0.7% of Summit Global Investments’ holdings, making the stock its 16th biggest holding. Summit Global Investments’ holdings in Eli Lilly and Company were worth $14,319,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Invera Wealth Advisors LLC grew its position in Eli Lilly and Company by 16.1% in the third quarter. Invera Wealth Advisors LLC now owns 1,812 shares of the company’s stock worth $2,097,000 after acquiring an additional 251 shares in the last quarter. Aprio Wealth Management LLC increased its stake in Eli Lilly and Company by 3.9% during the third quarter. Aprio Wealth Management LLC now owns 7,326 shares of the company’s stock worth $8,476,000 after acquiring an additional 274 shares during the last quarter. Modera Wealth Management LLC raised its position in Eli Lilly and Company by 6.5% during the third quarter. Modera Wealth Management LLC now owns 48,573 shares of the company’s stock valued at $56,202,000 after purchasing an additional 2,976 shares during the period. Greenup Street Wealth Management LLC raised its position in Eli Lilly and Company by 37.0% during the third quarter. Greenup Street Wealth Management LLC now owns 4,131 shares of the company’s stock valued at $4,780,000 after purchasing an additional 1,115 shares during the period. Finally, CFC Planning Co LLC lifted its stake in shares of Eli Lilly and Company by 53.5% in the 3rd quarter. CFC Planning Co LLC now owns 2,547 shares of the company’s stock valued at $2,949,000 after purchasing an additional 888 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock valued at $15,958,170 in the last three months. Company insiders own 0.14% of the company’s stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on LLY shares. Sanford C. Bernstein reiterated an “outperform” rating and issued a $1,450.00 target price on shares of Eli Lilly and Company in a report on Monday, October 26th. Guggenheim boosted their target price on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a research report on Friday, September 18th. Berenberg Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price target on the stock in a report on Tuesday, September 15th. HSBC raised their price target on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a research report on Thursday, September 10th. Finally, Weiss Ratings lowered shares of Eli Lilly and Company from a “buy (b+)” rating to a “buy (b)” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,398.43.

View Our Latest Research Report on LLY

Eli Lilly and Company Trading Down 0.1%

Shares of NYSE LLY opened at $1,415.64 on Monday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The business’s 50 day moving average price is $1,197.72 and its 200-day moving average price is $1,092.57. Eli Lilly and Company has a fifty-two week low of $834.19 and a fifty-two week high of $1,449.68. The company has a market cap of $1.33 trillion, a price-to-earnings ratio of 45.95, a PEG ratio of 1.80 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. The business had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business’s revenue was up 38.6% compared to the same quarter last year. During the same quarter last year, the firm posted $7.02 earnings per share. On average, sell-side analysts expect that Eli Lilly and Company will post 35.18 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 22.46%.

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.